The U.S. Food and Drug Administration (FDA) has approved Abeona Therapeutics’ gene therapy, Zevaskyn (prademagene zamikeracel), for treating wounds in patients with recessive dystrophic epidermolysis bullosa (RDEB), a rare and…
FDA
-
-
On February 16, 2024, the U.S. FDA approved the first adoptive tumour-infiltrating lymphocyte (TIL) T cell therapy, Amtagvi (lifileucel). This is a significant step in oncology, as the first FDA-approved…
-
The novel kind of cancer immunotherapy known as chimeric antigen receptor (CAR) T-cell treatment has prompted the US Food and Drug Administration (FDA) to announce an investigation into the potential…